September 2019, Volume 5, Issue 11

September 2019

Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.

Table of Contents

September 2019 Issue

Mikkael Sekeres, MD, MS

Our Identity Crisis

Sunday, September 1st, 2019
I recently embarked on a quest to determine who we are and what we do as hematologists. I figured it couldn’t be that hard, getting...

Poetry in Practice

Sunday, September 1st, 2019
In our July issue, ASH Clinical News Editor-in-Chief Mikkael Sekeres, MD, MS, outlined his goal to bring humanity back to patient notes in an...

September 2019 Issue

The Society Pages

Remembering Eugene Frenkel, AMA Announces Reimagining Residency Initiative Award Recipients, and more

Sunday, September 1st, 2019
Remembering Eugene P. Frenkel (1929 – 2019) Eugene P. Frenkel, MD, a National Cancer Institute investigator known for his research linking vitamin B12 metabolism and...
ASH Directions

ASH Sickle Cell Initiative Wins Top ASAE Prize, ASH-a-Palooza 2019 Announced, and more

Sunday, September 1st, 2019
ASH Sickle Cell Disease Initiative Wins Top ASAE Prize The American Society of Hematology (ASH) is proud to have been named a 2019 Power of...

September 2019 Issue

Taking the Pulse of Health Care and Politics

Sunday, September 1st, 2019
With more health-related topics becoming politicized, it may be hard to keep politics out of the exam room. As another U.S. presidential election approaches, Americans...
Dr. Altman with her family

Pulling Back the Curtain: Jessica K. Altman, MD

Sunday, September 1st, 2019
In this edition, Jessica K. Altman, MD, explains how working as a dental assistant helped shape her interactions with her patients. Tell us about your childhood.  I...

Demystifying Proteomics in Hematology

Sunday, September 1st, 2019
The central dogma of molecular biology describes the flow of information in a cell, from the DNA in a gene to RNA to protein....

September 2019 Issue

You Make the Call

Reader Responses: How would you treat a patient with CLL who developed warm autoimmune...

Sunday, September 1st, 2019
Here’s how readers responded to a You Make the Call question about a patient with CLL who developed warm autoimmune hemolytic anemia. Disclaimer: ASH does...
You Make the Call

How would you treat a patient with CLL who developed warm autoimmune hemolytic anemia?

Sunday, September 1st, 2019
This month, Dr. Jacobsen discusses how to treat a patient with chronic lymphocytic leukemia who develops warm autoimmune hemolytic anemia. And don't forget to check...

September 2019 Issue

Pregnancy History and Sex of Red Cell Donors Does Not Increase Mortality Risk for...

Sunday, September 1st, 2019
Previous research has suggested that receipt of a red blood cell (RBC) transfusion from a female donor who has ever been pregnant increases mortality...

NIH Releases New Requirements for Fetal Tissue Research Funding

Sunday, September 1st, 2019
The National Institutes of Health (NIH) revised its grant application guidance for researchers planning to use fetal tissue, requiring that researchers comply with the...

FDA Requires Boxed Warning for Tofacitinib

Sunday, September 1st, 2019
The U.S. Food and Drug Administration (FDA) has issued a Safety Announcement for the Janus kinase (JAK) inhibitor tofacitinib, after finding that patients taking...
Blood donation

Facebook Unveils U.S. Blood Donation Tool

Sunday, September 1st, 2019
Facebook has launched a blood donation feature on its U.S. platform to connect its users to donation centers in their neighborhoods and facilitate notifications...

Scientists Develop DNA Microscope to See as the Cell Sees

Sunday, September 1st, 2019
Researchers at the Massachusetts Institute of Technology and Harvard University have developed a technique allowing them to see the exact order of nucleotides within...

Certain Non-Hodgkin Lymphoma Subtypes Carry Higher Risk of Infection-Related Solid Tumor Cancers

Sunday, September 1st, 2019
Various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), carry a risk for second infection-related solid...

WHO Updates List of Essential Medicines and Diagnostic Tests

Sunday, September 1st, 2019
The World Health Organization (WHO) has added several new cancer drugs and diagnostics to the list of medicines and tests that it considers “essential”...

Early Vena Cava Filter Placement Fails to Reduce Embolic Risk in Severely Injured Patients

Sunday, September 1st, 2019
Placement of an inferior vena cava (IVC) filter in patients with a contraindication to prophylactic anticoagulation who have recently been admitted to the hospital...
WIB_icon

Estimated Prevalence of JAK2 V617F Mutations High in General Danish Population

Sunday, September 1st, 2019
The driver mutation JAK2 V617F and Calreticulin (CALR) mutations constitute major diagnostic criteria of myeloproliferative neoplasms (MPNs), and, while JAK2 V617F has been detected...
WIB_icon

Risk of Severe GVHD Lower With Post-Transplant Cyclophosphamide Than ATG in Mismatched Unrelated Donor...

Sunday, September 1st, 2019
Antithymocyte globulin (ATG) is considered standard graft-versus-host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) who undergo transplantation with a mismatched unrelated...

September 2019 Issue

On location

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

Sunday, September 1st, 2019
The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
On location

Guadecitabine Performs No Better Than Other Hypomethylating Agents in Treatment-Naïve Acute Myeloid Leukemia

Sunday, September 1st, 2019
Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) show that this...
On location

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A

Sunday, September 1st, 2019
In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates...
On location

Allogeneic or Autologous Transplant for Peripheral T Cell Lymphoma?

Sunday, September 1st, 2019
In a final analysis from the Autologous or Allogeneic Transplantation in T-Cell Lymphoma (AATT) trial, researchers found no differences in survival outcomes between consolidation...
On location

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

Sunday, September 1st, 2019
In a phase III trial of patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing comorbidities, a fixed-duration regimen of obinutuzumab plus venetoclax...

SHARE